7 Amendments of Sirpa PIETIKÄINEN related to 2021/2013(INI)
Amendment 77 #
Motion for a resolution
Recital C
Recital C
C. whereas the pharmaceutical strategy covers the full cycle of medicines, including research, manufacturing, testing, authorisation, consumption and disposal, and contributes to meeting the objectives of the European Green Deal, the digital transformation and climate neutrality;
Amendment 86 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
C a. whereas to make Europe fit for the future, the strategy must focus on strengthening the innovative potential of European pharmaceutical research; whereas this requires a close link with the EU industrial strategy and the European Health Data Space
Amendment 251 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
Amendment 307 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7 a. Stresses the need to take gender into account in the research, diagnosis, treatment and impact of medicines and therapeutics as women across the lifespan remain under-represented in biomedical and health research and data; underlines that consequently, the evidence base is weaker for women as well as for older people, leading to many conditions being underdiagnosed with women, such as cardiovascular disease; underlines that to reduce inequalities and health disparities, sex and gender must be balanced and incorporated in research throughout the process from stem cell testing to design of clinical trial protocols, data analysis, health technology assessment and access to care;
Amendment 369 #
Motion for a resolution
Paragraph 10 a (new)
Paragraph 10 a (new)
10 a. Highlights the need to set a minimum level of public procurement produced within Europe for medical devices , personal protective equipment, medicines and such to be set at least 30%;
Amendment 424 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Insists that a competitive EU pharmaceutical industry is strategic, fosters innovation and is more responsive to patients’ needs; points out that the industry needs a stable, flexible and agile regulatory environment; believes that it can thrive globally with a clear, robust and efficient intellectual property system; welcomes the initiative to build interoperable digital infrastructure for the European Health Data Space;
Amendment 587 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Recalls that the EU’s open strategic autonomy is linked to the constant and sufficient availability of medicines in all Member States; calls on the Commission to develop an early warning system for drug shortages, based on a European information network on supply problems, to increase public-private collaboration and to monitor the obligation on the part of industry to provide early and transparent information on the availability of medicines; calls on the Commission to develop a mechanism to safeguard transparency in production and supply chains in the event of emergencies; and create an emergency preparedness plan to fast track an increase in the production capacity so that it is sufficient to fulfil Union needs for the medicinal products in times of crisis and unexpected demand;